Evidence map›Paper›PMID 34305809›Full record

Trial reportFrontiers in endocrinology2021

Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial.

Louay Y Zaghlol, Amir F Beirat, Justin Z Amarin, Amro M Hassoun Al Najar, Yazan Y Hasan, Abdallah Qtaishat, Michael E Tierney, Raja Y Zaghlol, Ayman A Zayed

Registry-linked trialOpen access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04237493. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04237493 phase4completed

Effect of Dosage Reduction of Glucose-Lowering Multidrug Regimens on the Incidence of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: An Open-Label, Parallel-Group, Randomized, Controlled Trial

Ran2017Enrolled687Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsMetformin and Glimepiride (Low Dosage), Metformin and Glimepiride (Regular Dosage), Metformin and Insulin Glargine U100 (Low Dosage), Metformin and Insulin Glargine U100 (Regular Dosage), Metformin and Vildagliptin (Low Dosage)
Open the trial in the graph
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Ramadan and Diabetes: What About Non-Fasting Patients with Diabetes?Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Louay Y ZaghlolThe University of Jordan School of Medicine, Amman, Jordan.
Amir F BeiratThe University of Jordan School of Medicine, Amman, Jordan.
Justin Z AmarinThe University of Jordan School of Medicine, Amman, Jordan.
Amro M Hassoun Al NajarThe University of Jordan School of Medicine, Amman, Jordan.
Yazan Y HasanThe University of Jordan School of Medicine, Amman, Jordan.
Abdallah QtaishatThe University of Jordan School of Medicine, Amman, Jordan.
Michael E TierneyHunter-New England Health, New Lambton, NSW, Australia.
Raja Y ZaghlolDivision of Internal Medicine, MedStar Georgetown University Hospital/Washington Hospital Center, Washington, DC, United States.
Ayman A ZayedDepartment of Internal Medicine, The University of Jordan School of Medicine, Amman, Jordan.
University of Jordan · JOHunter New England Local Health District · AUMedStar Georgetown University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: We aimed to investigate the effect of dosage reduction of four hypoglycemic multidrug regimens on the incidences of acute glycemic complications in people with type 2 diabetes who fast during Ramaḍān. Methods: We conducted an open-label, parallel-group, randomized controlled trial at a tertiary care center in Amman, Jordan. We recruited adults with type 2 diabetes who expressed an intention to fast during Ramaḍān and were adherent to one of four regimens-namely: metformin and glimepiride; metformin and vildagliptin; metformin and insulin glargine U100; or, metformin, insulin glargine U100, and human regular insulin. We randomly assigned participants in a 2:1 ratio to low- or regular-dosage therapy. The primary outcomes were the incidences of hypoglycemia and hyperglycemia during the 29 days of Ramaḍān 2017, and the secondary outcomes were the incidences of diabetic ketoacidosis and hyperosmolar hyperglycemic state during the same period. Results: We randomly assigned 687 participants to low-dosage therapy ( Conclusion: Dosage reduction decreases the incidence of hypoglycemia without a concomitant increase in the incidences of hyperglycemia, diabetic ketoacidosis, and hyperosmolar hyperglycemic state in people with type 2 diabetes who fast during Ramaḍān. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT04237493.

Indexed as

AgedBlood GlucoseDiabetes Mellitus, Type 2Drug Therapy, CombinationFastingFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin GlargineIslamMaleMetforminMiddle AgedSulfonylurea CompoundsVildagliptinBlood GlucoseglimepirideHypoglycemic AgentsInsulin GlargineMetforminSulfonylurea CompoundsVildagliptinfastinghyperglycemiahypoglycemiahypoglycemic agentstype 2 diabetes mellitus

Identifiers

PMID34305809
PMCPMC8294055
OpenAlexW3180892985

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.